Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Pancreas Cancer
84%
Overall Survival
72%
Diseases
36%
Neoadjuvant Therapy
35%
Neoadjuvant Chemotherapy
27%
Malignant Neoplasm
27%
Pancreatectomy
27%
Chemotherapy
26%
Pancreaticoduodenectomy
24%
Recurrence Free Survival
23%
Recurrent Disease
20%
Pancreas Islet Cell Tumor
20%
Adjuvant Therapy
19%
Neoplasm
18%
Cancer
18%
Adjuvant Chemotherapy
16%
Biological Marker
16%
Intraductal Papillary Mucinous Tumor
16%
Next Generation Sequencing
16%
Tumor
15%
Prognostic Factor
14%
Hazard Ratio
13%
Radiation Therapy
12%
Personalized Medicine
12%
Cholangiocarcinoma
12%
Hepatocellular Carcinoma
12%
Retroperitoneal Lymph Node Dissection
10%
Treatment Response
10%
Endoscopic Ultrasound
9%
Pancreatic Surgery
9%
Somatic Mutation
9%
Genetics
9%
Cancer Surgery
8%
Pancreatic Duct
8%
Dysplasia
8%
Stereotactic Body Radiation Therapy
8%
CA 19-9 Antigen
8%
T Cell
8%
Lymph Node
8%
Circulating Tumor Cell
8%
Retrovirus Vector
8%
Patient-Derived Organoid
8%
Preoperative Chemotherapy
7%
CA19-9
7%
Proportional Hazards Model
7%
Median Follow Up
7%
Endoscopic Ultrasound Guided Fine Needle Biopsy
7%
Cancer Staging
7%
Odds Ratio
6%
Keyphrases
Pancreatic Ductal Adenocarcinoma
96%
Pancreatic Cancer
89%
Overall Survival
50%
Resection
40%
Neoadjuvant Therapy
35%
Recurrence-free Survival
24%
Neoadjuvant Chemotherapy
24%
Pancreatectomy
20%
Hepatocellular Carcinoma
20%
Neoadjuvant
19%
Adjuvant Therapy
19%
Pancreaticoduodenectomy
19%
Tumor
18%
Median Overall Survival
17%
Locally Advanced Pancreatic Cancer
17%
Pancreatic Neuroendocrine Tumors (pNETs)
16%
Next-generation Sequencing
16%
Surgical Resection
16%
Metastatic Pancreatic Ductal Adenocarcinoma
16%
Carbohydrate Antigen 19-9 (CA19-9)
16%
FOLFIRINOX
14%
Borderline Resectable
14%
Patient-derived Organoids
12%
Adjuvant Chemotherapy
12%
Cancer Patients
12%
Precision Medicine
12%
Intraductal Papillary mucinous Neoplasm
12%
Chimeric Antigen Receptor T Cells (CAR-T)
12%
Pharmacotyping
12%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
11%
Prognostic Factors
11%
Oncological Outcomes
11%
High Risk
11%
Treatment Response
11%
Single Institution
10%
Prognostic Biomarker
10%
Pancreatic Adenocarcinoma
9%
Tumor Microenvironment
9%
Hazard Ratio
9%
T Cells
9%
Metastasis
9%
Nodal Disease
9%
Somatic mutation
9%
Multidisciplinary Clinic
9%
Liver Metastasis
8%
Lymphocytes
8%
Prognostic Value
8%
Clinical Outcomes
8%
Circulating Tumor Cells
8%
Nivolumab
8%